Opicapone Efficacy and Tolerability in Parkinson's Disease Patients Reporting Insufficient Benefit/Failure of Entacapone

BACKGROUND: Opicapone, a recently introduced catechol‐o‐methyl transferase (COMT) inhibitor has the advantage of being administered once daily, and has pharmacokinetic data to indicate it offers a greater degree of COMT inhibition than entacapone. Although trial data indicate it is non‐inferior to e...

Descripción completa

Detalles Bibliográficos
Autores principales: Vokurka, Petr, Barron, Andrew, Sumaria, Sheetal, Stockford, Lindsey, Jarman, Paul, Bhatia, Kailash, Farmer, Simon, Saifee, Tabish, Warner, Tom, Weil, Rimona, Gandhi, Sonia, Limousin, Patricia, Korlipara, Prasad, Foltynie, Tom
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2020
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7604656/
https://www.ncbi.nlm.nih.gov/pubmed/33163567
http://dx.doi.org/10.1002/mdc3.13094

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7604656/
https://www.ncbi.nlm.nih.gov/pubmed/33163567
http://dx.doi.org/10.1002/mdc3.13094

Ejemplares similares